There are over 150 companies listed on the ASX that fall under the Lifesciences banner. This includes medical device manufacturers, drug development companies and the emerging 'e-health' companies. However, the reality is that with the exception of a handful of names, like Cochlear and CSL Ltd, most of these stocks fly under the radar of most investors. Livewire hosted a discussion following the recent Bioshares Investment Summit to understand the opportunities available in this overlooked sector. Adam Allcock from Katana hosts Andy Gracey from Australian Ethical and Stuart Roberts from NDF Research. The panel discusses the rise of technology, what they look for when choosing investments, managing risks and each panelist shares one of their top picks following the summit. So if your portfolio is in need of a booster shot why not tune in to this latest exclusive bought to you by Livewire.